{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:25:16Z","timestamp":1767846316577,"version":"3.49.0"},"reference-count":57,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473065"],"award-info":[{"award-number":["81473065"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>We aimed to evaluate the status and barriers related to hepatitis C virus (HCV) treatment among Chinese methadone maintenance treatment (MMT) clients, and the willingness and barriers of patients to accept directly observed treatment (DOT) service and oral direct-acting antivirals (DAAs). We conducted a cross-sectional survey from July to October 2017 in Guangdong Province, China, involving 678 HCV antibody-positive MMT patients. If they reported being infected with HCV, then their HCV treatment experience, willingness to use DOT and DAAs, along with any barriers, were collected. Logistic regression analysis was used to identify the correlates of initiating HCV treatment. Among those reporting HCV infection (54%, 366\/678), 39% (144\/366) initiated treatment; however, 38% (55\/144) interrupted and 55% (79\/135) delayed treatment for 15 months. Seventy-five percent (273\/366) and 53% (195\/366) were willing to use DOT and DAAs, respectively. Unaffordable medical costs and insignificant symptoms were the major barriers to HCV treatment and accepting DOT or DAAs. The lack of a stable residence, being a woman, and having ever injected drugs were all associated with a low probability of initiating treatment (p &lt; 0.05). This study highlights a limited uptake of HCV treatment among MMT patients, and a need to strengthen the popularity of DOT and DAAs and integrate them into Chinese MMT clinics.<\/jats:p>","DOI":"10.3390\/ijerph16224436","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T09:11:27Z","timestamp":1573636287000},"page":"4436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Yin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-8890","authenticated-orcid":false,"given":"Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"ref_1","unstructured":"WHO (2017). Global Hepatitis Report, World Health Organization."},{"key":"ref_2","first-page":"940","article-title":"Primary risk factors of hepatitis C virus infection: A Meta-analysis","volume":"32","author":"Su","year":"2011","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","unstructured":"Office of China National Narcotics Control Commission (2017). Annual Report on Drug Control in China, 2017, Ministry of Public Security."},{"key":"ref_5","unstructured":"Lin, G., Dongmin, L., Peilong, L., Wei, G., and Yan, C. (2017). Population specific sentinel surveillance for HIV infection, syphilis and HCV infection in China, during 2010\u20132015. Dis. Surveill., 32."},{"key":"ref_6","unstructured":"WHO (2016). Global Health Sector Strategy on Viral Hepatitis, 2016\u20132021, World Health Organization."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1086\/427450","article-title":"Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities","volume":"40","author":"Litwin","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.15102","article-title":"Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes","volume":"49","author":"Li","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e008162","DOI":"10.1136\/bmjopen-2015-008162","article-title":"Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: A 7-year retrospective cohort study","volume":"5","author":"Zou","year":"2015","journal-title":"BMJ Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/10826084.2014.957768","article-title":"Methadone maintenance therapy and HIV counseling and testing are associated with lower frequency of risky behaviors among injection drug users in China","volume":"50","author":"Wang","year":"2015","journal-title":"Subst. Use Misuse"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhuang, X., Liang, Y., Chow, E.P., Wang, Y., Wilson, D.P., and Zhang, L. (2012). HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: A systematic review and meta-analysis. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-130"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jsat.2010.02.002","article-title":"High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin","volume":"38","author":"Waizmann","year":"2010","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/ADM.0b013e3181add3de","article-title":"Successful integration of hepatitis C evaluation and treatment services with methadone maintenance","volume":"4","author":"Harris","year":"2010","journal-title":"J. Addict. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.drugpo.2007.01.009","article-title":"Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection","volume":"18","author":"Grebely","year":"2007","journal-title":"Int. J. Drug Policy"},{"key":"ref_15","first-page":"906","article-title":"The guideline of prevention and treatment for hepatitis C: A 2015 update","volume":"23","author":"Wei","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chin. J. Hepatol."},{"key":"ref_16","unstructured":"WHO (2016). Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection, World Health Organization."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/00952990.2011.643974","article-title":"Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China","volume":"38","author":"Du","year":"2012","journal-title":"Am. J. Drug Alcohol Abuse."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12954-017-0197-3","article-title":"Hepatitis C infection, related services, and barriers to HCV treatment among drug users in methadone maintenance treatment (MMT) clinics in Shanghai, China","volume":"14","author":"Li","year":"2017","journal-title":"Harm Reduct. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2147\/PPA.S49113","article-title":"Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: A literature review","volume":"7","author":"Mravcik","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4254\/wjh.v9.i33.1239","article-title":"Global elimination of hepatitis C virus infection: Progresses and the remaining challenges","volume":"9","author":"Taherkhani","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_21","unstructured":"(2019, March 27). The Directorate-General Approves the Listing of Dalapitavir Hydrochloride Tablets and Aspirin Soft Capsules, Available online: http:\/\/www.sda.gov.cn\/WS01\/CL0051\/172150.html."},{"key":"ref_22","first-page":"73","article-title":"Hepatitis C virus and the kidney","volume":"15","author":"Pol","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"ref_23","unstructured":"China National Narcotic Control Committee (2017). China Drug Report, China National Narcotic Control Committee."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2019.02.002","article-title":"Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study","volume":"399","author":"Marciniewicz","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zhang, D., Chen, W., Zou, X., and Ling, L. (2013). High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076931"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, C., Shi, C.X., Rou, K., Zhao, Y., Cao, X., Luo, W., Liu, E., and Wu, Z. (2016). Baseline HCV Antibody Prevalence and Risk Factors among Drug Users in China\u2019s National Methadone Maintenance Treatment Program. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147922"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s11606-015-3209-6","article-title":"Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program","volume":"30","author":"Trooskin","year":"2015","journal-title":"J. Gen. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jvh.12507","article-title":"Public health clinic-based hepatitis C testing and linkage to care in Baltimore","volume":"23","author":"Mehta","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.2105\/AJPH.2012.300874","article-title":"Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users","volume":"103","author":"Havens","year":"2013","journal-title":"Am. J. Public Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","article-title":"Revisiting the behavioral model and access to medical care: Does it matter?","volume":"36","author":"Andersen","year":"1995","journal-title":"J. Health Soc. Behav."},{"key":"ref_32","unstructured":"(2019, March 30). Notice on Printing and Distributing Methods for the Administration of Drug Maintenance Treatment, Available online: http:\/\/www.nhfpc.gov.cn\/jkj\/s3584\/201701\/0a97d574cf4744e1bbc335ed5de315b9.shtml."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/03007995.2018.1546678","article-title":"Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C","volume":"35","author":"Wu","year":"2018","journal-title":"Curr. Med Res. Opin."},{"key":"ref_34","first-page":"e0195117","article-title":"Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China","volume":"13","author":"Lu","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40261-018-0702-9","article-title":"Cost-Effectiveness of Elbasvir\/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China","volume":"38","author":"Chen","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_36","unstructured":"(2019, September 05). Notice of the Ministry of Human Resources and Social Security of the National Healthcare Security Administration on Printing and Distributing the Catalogue of National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs, Available online: http:\/\/www.nhsa.gov.cn\/art\/2019\/8\/20\/art_37_1666.html."},{"key":"ref_37","first-page":"512","article-title":"HCV infection and liver fibrosis among drug users in methadone maintenance treatment clinics","volume":"23","author":"Lang","year":"2017","journal-title":"China J. AIDS STD"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2010.06238.x","article-title":"Reinfection with hepatitis C virus following sustained virological response in injection drug users","volume":"25","author":"Grebely","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: A population-based cohort study","volume":"2","author":"Islam","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cipriano, L.E., and Goldhaber-Fiebert, J.D. (2018). Population Health and Cost-Effectiveness Implications of a \u201cTreat All\u201d Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract., 3.","DOI":"10.1177\/2381468318776634"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/ciu066","article-title":"Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus\u2013Infected Patients in a Country With Limited Resources: The Case of Egypt","volume":"58","author":"Obach","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jvh.12008","article-title":"Accessing Hepatitis C patients who are difficult to reach: It is time to overcome barriers","volume":"19","author":"Bruggmann","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1515\/jtim-2017-0017","article-title":"Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic","volume":"5","author":"Crowley","year":"2017","journal-title":"J. Transl. Int. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1525-1497.2003.20826.x","article-title":"\u201cThey treated me like a leper\u201d. Stigmatization and the quality of life of patients with hepatitis C","volume":"18","author":"Zickmund","year":"2003","journal-title":"J. Gen. Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1353\/hpu.0.0068","article-title":"Association between the level of housing instability, economic standing and health care access: A meta-regression","volume":"19","author":"Reid","year":"2008","journal-title":"J. Health Care Poor Underserved"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2893.2012.01648.x","article-title":"Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients","volume":"19","author":"Charlebois","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2893.2007.00849.x","article-title":"Health professionals\u2019 attitudes toward caring for people with hepatitis C","volume":"14","author":"Richmond","year":"2007","journal-title":"J. Viral Hepat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2648.2010.05516.x","article-title":"Hepatitis C virus in primary care: Survey of nurses\u2019 attitudes to caring","volume":"67","author":"Frazer","year":"2011","journal-title":"J. Adv. Nurs."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","article-title":"Barriers associated with the treatment of hepatitis C virus infection among illicit drug users","volume":"93","author":"Grebely","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"Mehta","year":"2006","journal-title":"AIDS"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jgh.12421","article-title":"Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues","volume":"29","author":"Liu","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Wang, H., Swann, R., Thomas, E., Innes, H.A., Valerio, H., Hayes, P.C., Allen, S., Barclay, S.T., Wilks, D., and Fox, R. (2018). Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. J. Viral Hepat.","DOI":"10.1111\/jvh.12897"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ii29","DOI":"10.1093\/ije\/dyq210","article-title":"Scaling up the national methadone maintenance treatment program in China: Achievements and challenges","volume":"39","author":"Yin","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1097\/01.aids.0000432470.46379.dd","article-title":"Hepatitis C virus\/HIV coinfection and responses to initial antiretroviral treatment","volume":"27","author":"Hua","year":"2013","journal-title":"AIDS"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/liv.13626","article-title":"Treatment of hepatitis C: The use of the new pangenotypic direct-acting antivirals in \u201cspecial populations\u201d","volume":"38","author":"Pol","year":"2018","journal-title":"Liver Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J. Viral Hepat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2018.02.003","article-title":"Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs","volume":"32","author":"Martinello","year":"2018","journal-title":"Infect. Dis. Clin. N. Am."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/22\/4436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:33:52Z","timestamp":1760189632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/22\/4436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":57,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["ijerph16224436"],"URL":"https:\/\/doi.org\/10.3390\/ijerph16224436","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]}}}